REFERENCES / SOURCE STATE

CJC-1295 references: the full cited record

Every quantitative claim on this site resolves to one of the studies below. Authors, journal, year, DOI, and PubMed link for each — the source state behind every figure.

How this reference list works

This is the source state for the entire CJC-1295 review. Each inline [N] marker on the research, pharmacokinetics, DAC-vs-no-DAC, dosage, and FAQ pages corresponds to a numbered entry here. The human pharmacokinetic core rests on three studies — Teichman 2006 [1], Jette 2005 [2], and Ionescu and Frohman 2006 [3] — supported by the mouse growth study [4], the proteomic biomarker work [5], the GHRH-degradation and substitution chemistry [7][8], and the analytical and review literature [6][13][14][15].

Where a registry value is contested — the molecular formula and CAS attribution for the DAC variant differ across chemical-supplier sources — this review flags the disagreement rather than asserting a single figure. The full reference list below is the record this site is built on; nothing on the site makes a quantitative claim that is not traceable to one of these entries.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477.
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650.
  7. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency (D-Ala2 GHRH analog study). 1994.
  8. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540.
  9. Modified GRF (1-29): tetrasubstituted hGRF(1-29) without the DAC albumin-binding moiety; short-acting no-DAC form. Reference overview.
  10. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men (GRF 1-29 pharmacokinetics study). 1986.
  11. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide (ipamorelin PK-PD study). Pharm Res. 1999.
  12. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003.
  13. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195.
  14. Advances in the detection of growth hormone releasing hormone synthetic analogs (GHRH-analog detection review). Drug Test Anal. 2021.
  15. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS (immunoaffinity GHRH-MS study). Anal Bioanal Chem. 2016.